NCT01309724

Brief Summary

Inadequate identification of and subsequent delayed therapy for patients with hypoperfusion (including hypovolemia, congestive heart failure and sepsis) is a common problem faced by physicians and intensivists caring for critically ill patients. Bedside clinical assessment is notoriously inaccurate in diagnosing complex etiologies of hemodynamic disturbances and in deciding on the appropriate therapy. Invasive techniques which are often required to guide diagnosis and therapy have significant risks associated with them, are costly, and are time consuming. New technology has been developed that allows for instantaneous, noninvasive monitoring of key hemodynamic parameters, like stroke volume, peak velocity and cardiac output. This new technology has the potential to improve recognition of the etiology of hemodynamic disturbances and assist the clinician in optimizing therapy based on changes in hemodynamic parameters. There is significant potential for this to be translated into improved outcomes in critically ill patients, but this has never been studied.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
92

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2010

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2010

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 2, 2011

Completed
5 days until next milestone

First Posted

Study publicly available on registry

March 7, 2011

Completed
Last Updated

March 7, 2011

Status Verified

March 1, 2011

Enrollment Period

11 months

First QC Date

March 2, 2011

Last Update Submit

March 3, 2011

Conditions

Keywords

HypotensionFluid

Outcome Measures

Primary Outcomes (1)

  • Time on vasopressors, measured during the 48 hours after study enrollment

    48 hours after study enrollment

Secondary Outcomes (8)

  • ICU length of stay

    At one month (average)

  • Hospital length of stay

    At one month (average)

  • Duration of mechanical ventilation

    At one month (average)

  • Development of acute renal failure

    At one month (average)

  • Invasive procedures performed after study enrollment

    At one month (average)

  • +3 more secondary outcomes

Study Arms (2)

Control

NO INTERVENTION

No measurements are made on the control group.

USCOM

EXPERIMENTAL

Patients undergo hemodynamic measurements with the ultrasound cardiac output monitor (USCOM). Fluid resuscitation is guided by USCOM measurements.

Other: USCOM-guided fluid administration

Interventions

Patients in the intervention group underwent hemodynamic measurements with the ultrasound cardiac output monitor. Based on these measurements, patients were guided through a fluid resuscitation protocol.

Also known as: Ultrasound cardiac output monitor
USCOM

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 yrs or greater
  • Administration of vasopressors, defined as a continuous infusion of norepinephrine at a dose \>5 mcg/min, dopamine ≥5 mcg/kg/min or any dose of another vasopressor
  • Passage of \<18 hours since initiation of vasopressors at doses specified above

You may not qualify if:

  • Hemorrhagic shock
  • Need for immediate surgery
  • Imminent risk of death in the next 48 hours (as judged by the attending ICU physician)
  • Level of care decision that precluded implementation of the study protocol
  • Enrollment in any other clinical study
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Barnes-Jewish Hospital

St Louis, Missouri, 63110, United States

Location

MeSH Terms

Conditions

Hypotension

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Study Officials

  • Lee M Demertzis, MD

    Barnes-Jewish Hospital

    PRINCIPAL INVESTIGATOR
  • Marin H Kollef, MD

    Washington University School of Medicine

    STUDY DIRECTOR
  • Warren Isakow, MD

    Washington University School of Medicine

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

March 2, 2011

First Posted

March 7, 2011

Study Start

January 1, 2010

Primary Completion

December 1, 2010

Study Completion

December 1, 2010

Last Updated

March 7, 2011

Record last verified: 2011-03

Locations